The potential of cannabinoids in managing cancer-related anorexia in older adults: a systematic review of the literature.
Ceolin et al.·The journal of nutrition, health & agingImpact 4.4
GemischtGRADEHoch4 Zitate
Stichprobek = 6 Studien n = 869 Pat.
DauerStudien zwischen 2002 und 2019…
KontrollePlacebo oder aktiver Komparator
EndpunktAppetit / Kalorienaufnahme
Verblindungdoppelblind
DesignSystematic Review
Cannabinoidthc
Max. Dosis20.0 mg
Applikationoral
”Kernaussage
Cannabinoide zeigen gemischte Ergebnisse: Megestrol acetate war wirksamer als Dronabinol; Nabilone 0,5 mg zeigte keine Überlegenheit gegenüber Placebo, aber bei doppelter Dosierung (1,0 mg nach 6 Wochen) signifikante Steigerung der Kalorienaufnahme; THC zeigte Gewichtszunahme ≥10% bei 17,6% der Patienten und verbesserte Appetit bei 2,5 mg-Dosen.
Zusammenfassung
Systematische Review zu Cannabinoiden bei Tumor-assoziierter Anorexie älterer Erwachsener; k=6 Studien (5 RCTs, 1 prospektive Studie), n=869 Teilnehmende (2002-2019). Megestrol 800 mg/d wirksamer als Dronabinol 2,5 mg 2×/d für Appetit. Nabilone 1,0 mg/d über 8 Wochen: signifikanter Anstieg Kalorienaufnahme und Kohlenhydratkonsum vs. Placebo. THC 5-10 mg/d: Gewichtszunahme ≥10% bei 17,6% der Patienten, verbesserte Chemosensorik und Appetit bei THC 2,5 mg vs. Placebo. Keine schwerwiegenden Nebenwirkungen berichtet.
P
PopulationÄltere Erwachsene mit krebsassoziierter Anorexie (Anorexia of Aging), gepoolt n=869
I
InterventionCannabinoide (Dronabinol, Nabilone, THC) in verschiedenen Dosierungen und Applikationsformen
C
KontrollePlacebo oder aktiver Komparator (Megestrol Acetat)
O
OutcomeGemischte Ergebnisse: Megestrol Acetat überlegen gegenüber Dronabinol 2,5 mg bei Appetitsteigerung; Nabilone 1,0 mg zeigte nach 8 Wochen signifikante Steigerung der Kalorienaufnahme vs. Placebo; THC-Dosen 2,5–10 mg verbesserten Chemosensorik und Appetit ohne signifikante Nebenwirkungen
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Hoch
Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.
Qualitätsprofil
Größe★★★★★
VerblindungDoppelblind
EffektstärkeGemischt
Zitate / Jahr★★★★★
Autoren
Ceolin C, De Rui M, Ravelli A, Papa MV, Devita M, Sergi G, Coin A
Background And Objectives: Anorexia of aging (AoA) is a prevalent geriatric syndrome characterized by a multifactorial decline in appetite and reduced food intake associated with the aging process. This systematic review aims to investigate the use and outcomes of cannabinoids in addressing AoA, with the goal of providing a comprehensive understanding and discussing their potential integration into daily clinical practice.
Methods: A thorough search of databases (Embase Ovid, Scopus, PubMed, Cochrane Library, and Web of Science) identified 6100 studies. After eliminating duplicates and screening titles and abstracts, 25 studies underwent full appraisal. Two reviewers assessed inclusion suitability, and study methodologies were evaluated using the Newcastle-Ottawa Scale (NOS) for observational studies and the modified Jadad Scoring Scale for randomized controlled trials. Ultimately, six studies published between 2002 and 2019, involving 869 participants, were included in the review.
Results: Out of the 6 fin. l papers selected, 5 were randomized trials, and 1 was a prospective study. Megestrol acetate (800 mg/d) proved to be more effective than dronabinol 2.5 mg twice a day in increasing appetite. Nabilone (at a dosage of 0.5 mg per day) did not show superiority over placebo in alleviating symptoms such as pain, nausea, loss of appetite, and weight. However, with a double dosage followed by 1.0 mg/6 weeks, after eight weeks of treatment, patients recorded a significant increase in calorie intake and carbohydrate consumption compared to the placebo group, with some patients also experiencing substantial weight gain. Regarding delta-9-tetrahydrocannabinol (THC), a weight increase of >/=10% was observed in 17.6% of patients with doses of 5 mg or 10 mg capsules daily, without significant side effects. Additionally, patients treated with THC 2.5 mg reported improved chemosensory perception and increased appetite before meals compared to placebo. No significant side effects were reported in older adults taking cannabinoids.
Conclusions: Cannabinoids offer promise in enhancing the quality of life for older individuals with active neoplastic disease. However, to establish comprehensive guidelines, further research with larger sample sizes is essential. Only through this approach can we fully grasp the potential and application of cannabinoids in addressing the nutritional concerns associated with neoplastic diseases.